1. Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma.
- Author
-
Capala, Marta E., Pachler, Katrin S., Lauwers, Iris, de Korte, Maarten A., Verkaik, Nicole S., Mast, Hetty, Jonker, Brend P., Sewnaik, Aniel, Hardillo, Jose A., Keereweer, Stijn, Monserez, Dominiek, Koljenovic, Senada, Mostert, Bianca, Verduijn, Gerda M., Petit, Steven, and van Gent, Dik C.
- Subjects
IN vivo studies ,HEAD & neck cancer ,RADIATION ,CHEMORADIOTHERAPY ,TREATMENT effectiveness ,RESEARCH funding ,CISPLATIN ,CELL proliferation ,BIOLOGICAL assay ,DNA damage ,PREDICTION models ,SQUAMOUS cell carcinoma ,CELL death ,DOSE-response relationship in biochemistry - Abstract
Simple Summary: The treatment outcomes in patients with head and neck cancer vary greatly, and serious side effects are often observed. Being able to predict therapy effects is therefore crucial for choosing the best treatment option for each patient. In this study, we developed an assay to evaluate how head and neck tumor cells respond to radiation and chemotherapy. Treatment of thin patient-derived cancer tissue slices in the laboratory (in vitro) resulted in large differences in individual tumor's reactions to treatment. In the sensitive tumors, cancer cells repaired the DNA damage inflicted by therapy only partially, stopped multiplying, and showed increased levels of cell death. On the other hand, resistant tumors were able to recover from the damage caused by the treatment. The next crucial step is to investigate whether the differences we observed in vitro can indeed predict the treatment outcomes; this is currently being tested in an ongoing clinical trial. Background: Head and neck squamous cell carcinoma (HNSCC) displays a large heterogeneity in treatment response, and consequently in patient prognosis. Despite extensive efforts, no clinically validated model is available to predict tumor response. Here we describe a functional test for predicting tumor response to radiation and chemotherapy on the level of the individual patient. Methods: Resection material of 17 primary HNSCC patients was cultured ex vivo, irradiated or cisplatin-treated, after which the effect on tumor cell vitality was analyzed several days after treatment. Results: Ionizing radiation (IR) affected tumor cell growth and viability with a clear dose-response relationship, and marked heterogeneity between tumors was observed. After a single dose of 5Gy, proliferation in IR-sensitive tumors dropped below 30% of the untreated level, while IR-resistant tumors maintained at least 60% of proliferation. IR-sensitive tumors showed on average a twofold increase in apoptosis, as well as an increased number and size of DNA damage foci after treatment. No differences in the homologous recombination (HR) proficiency between IR-sensitive and –resistant tumors were detected. Cisplatin caused a decrease in proliferation, as well as induction of apoptosis, again with marked variation between the samples. Conclusions: Our functional ex vivo assay discriminated between IR-sensitive and IR-resistant HNSCC tumors, and may also be suitable for predicting response to cisplatin. Its predictive value is currently under investigation in a prospective clinical study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF